Bimekizumab maintains efficacy through 3 years in psoriasis
Click Here to Manage Email Alerts
MILAN — Patients with psoriasis who initially responded to bimekizumab maintained that response through 3 years with maintenance dosing, according to an open label long-term extension trial
“The vast majority who are responding at week 16, no matter how you measure response, keep their response at 3 years,” Bruce E. Strober, MD, PhD, clinical professor of dermatology at Yale University School of Medicine and one of the study’s investigators, told Healio. “The clinical significance of this is that we can tell a patient if they stay on the drug, there’s a very high probability they will still do well for 3 years.”
Strober presented data from the BE BRIGHT open label extension (OLE) study, which included patients who completed the BE SURE, BE VIVID or BE READY clinical trials, at the European Academy of Dermatology and Venereology Congress.
All patients who completed one of the feeder trials were eligible to enter the BE BRIGHT OLE trial, where patients were randomly assigned to receive bimekizumab 320 mg every 4 weeks or every 8 weeks based on PASI response at the end of their respective feeder study. Based on PASI response and investigator discretion, some patients were switched from 4-week dosing to 8-week dosing at week 24 or week 48.
Of 989 patients who received the 4-week dosing at baseline, 87.7% achieved an improvement of at least 2 points in PASI, with 62.7% achieving PASI 100 at week 16.
The extension study included 503 patients who achieved PASI 100 at week 16. Of these, 89.3% maintained that response through 1 year and 82% maintained through 3 years.
Additionally, of those who had at least a 2-point improvement in PASI at week 16, 96.5% of those maintained that improvement through 1 year and 94.2% did so through 3 years.
“Bimekizumab works in the majority of patients at most outcome measures,” Strober said. “And it works really well long term in people who do well on the drug.”